Firm Represents Underwriters in CVS Health’s $40 Billion Debt Offering



Ryan R. Bekkerus Ryan R. Bekkerus
Roxane F. Reardon Roxane F. Reardon
Jonathan E. Cantor Jonathan E. Cantor
Michael R. Isby Michael R. Isby
Jeanne M. Annarumma Jeanne M. Annarumma
+2

The Firm recently represented the underwriters, led by Barclays Capital Inc., Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC, in connection with the public offering by CVS Health Corporation (“CVS Health”) of $40 billion of senior notes. The offering is the third-largest corporate bond sale on record. CVS Health intends to use the net proceeds from the offering to fund a portion of the purchase price of its acquisition of Aetna Inc., one of the nation’s leading diversified health care benefits companies.

The notes consisted of $1 billion of floating rate notes due 2020, $1 billion of floating rate notes due 2021, $2 billion of 3.125% senior notes due 2020, $3 billion of 3.35% senior notes due 2021, $6 billion of 3.7% senior notes due 2023, $5 billion of 4.1% senior notes due 2025, $9 billion of 4.3% senior notes due 2028, $5 billion of 4.78% senior notes due 2038 and $8 billion of 5.05% senior notes due 2048.

CVS Health is a pharmacy innovation company with more than 9,800 retail locations and more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 94 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan.

The Simpson Thacher team for the transaction included Roxane Reardon, Ryan Bekkerus, Jo Djekovic, Robert Meyer and Christine Turner (Capital Markets); Jonathan Cantor and John Torrenti (Tax); Noah Leibowitz (Intellectual Property); Michael Isby (Environmental); Jeanne Annarumma and Patricia Adams (ECEB); and Jennie Getsin (FINRA/Blue Sky).

Team and Contacts